Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 9, 2011, Pages 1130-1137

  Feng, Bo ^a   Xu, Lei ^a   Wang, Hua ^a   Yan, Xinfeng ^a   Xue, Junli ^a   Liu, Fengjing ^a,b   Hu, Ji Fan ^b  

^a TONGJI UNIVERSITY   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AGE; Atherosclerosis; Atorvastatin; Diabetes; RAGE; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ATORVASTATIN; GLUCOSE; GLUTATHIONE; MANNITOL; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID DIET; MALE; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RISK REDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

ANIMALS; HEPTANOIC ACIDS; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; OXIDATIVE STRESS; PYRROLES; RATS; RECEPTORS, IMMUNOLOGIC;

RATTUS;

EID: 79960561215     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.05.007     Document Type: Article

References (69)

1. Grundy S.M., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., Howard B.V., Mitch W., Smith S.C., Sowers J.R. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999, 100:1134-1146.
2. King T.J., Fukushima L.H., Donlon T.A., Hieber A.D., Shimabukuro K.A., Bertram J.S. Correlation between growth control, neoplastic potential and endogenous connexin43 expression in HeLa cell lines: implications for tumor progression. Carcinogenesis 2000, 21:311-315.
3. Pyorala K., Uusitupa M., Laakso M., Siitonen O., Niskanen L., Ronnemaa T. Macrovascular complications in relation to hyperinsulinaemia in non-insulin-dependent diabetes mellitus. Diabete Metab. 1987, 13:345-349.
4. Candido R., Jandeleit-Dahm K.A., Cao Z., Nesteroff S.P., Burns W.C., Twigg S.M., Dilley R.J., Cooper M.E., Allen T.J. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002, 106:246-253.
5. Forbes J.M., Yee L.T., Thallas V., Lassila M., Candido R., Jandeleit-Dahm K.A., Thomas M.C., Burns W.C., Deemer E.K., Thorpe S.R., Cooper M.E., Allen T.J. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004, 53:1813-1823.
6. Goldberg I.J. Why does diabetes increase atherosclerosis? I don't know!. J. Clin. Invest. 2004, 114:613-615.
7. Falcone C., Emanuele E., D'Angelo A., Buzzi M.P., Belvito C., Cuccia M., Geroldi D. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1032-1037.
8. Baynes J.W., Thorpe S.R. Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. 2000, 28:1708-1716.
9. Sano H., Nagai R., Matsumoto K., Horiuchi S. Receptors for proteins modified by advanced glycation endproducts (AGE)-their functional role in atherosclerosis. Mech. Ageing Dev. 1999, 107:333-346.
10. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M., Wautier J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. 2001, 280:E685-E694.
11. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 2001, 108:949-955.
12. Hori O., Brett J., Slattery T., Cao R., Zhang J., Chen J.X., Nagashima M., Lundh E.R., Vijay S., Nitecki D., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 1995, 270:25752-25761.
13. Bucciarelli L.G., Wendt T., Qu W., Lu Y., Lalla E., Rong L.L., Goova M.T., Moser B., Kislinger T., Lee D.C., Kashyap Y., Stern D.M., Schmidt A.M. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002, 106:2827-2835.
14. Cuccurullo C., Iezzi A., Fazia M.L., De Cesare D., Di Francesco A., Muraro R., Bei R., Ucchino S., Spigonardo F., Chiarelli F., Schmidt A.M., Cuccurullo F., Mezzetti A., Cipollone F. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2716-2723.
15. Takeda R., Suzuki E., Satonaka H., Oba S., Nishimatsu H., Omata M., Fujita T., Nagai R., Hirata Y. Blockade of endogenous cytokines mitigates neointimal formation in obese Zucker rats. Circulation 2005, 111:1398-1406.
16. Zhong Y., Li S.H., Liu S.M., Szmitko P.E., He X.Q., Fedak P.W., Verma S. C-Reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension 2006, 48:504-511.
17. Gu L., Hagiwara S., Fan Q., Tanimoto M., Kobata M., Yamashita M., Nishitani T., Gohda T., Ni Z., Qian J., Horikoshi S., Tomino Y. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol. Dial. Transplant. 2006, 21:299-313.
18. Ha H., Yu M.R., Choi Y.J., Kitamura M., Lee H.B. Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J. Am. Soc. Nephrol. 2002, 13:894-902.
19. Yamagishi S., Inagaki Y., Okamoto T., Amano S., Koga K., Takeuchi M., Makita Z. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J. Biol. Chem. 2002, 277:20309-20315.
20. Ito T., Ikeda U. Inflammatory cytokines and cardiovascular disease. Curr. Drug Targets Inflamm. Allergy 2003, 2:257-265.
21. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., Fuller J.H. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
22. Group H.P.S.C. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
23. Grothusen C., Bley S., Selle T., Luchtefeld M., Grote K., Tietge U.J., Drexler H., Schieffer B. Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis. Atherosclerosis 2005, 182:57-69.
24. Yoshida M. Potential role of statins in inflammation and atherosclerosis. J. Atheroscler. Thromb. 2003, 10:140-144.
25. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1712-1719.
26. Lin C.P., Chen Y.H., Lin W.T., Leu H.B., Liu T.Z., Huang S.L., Chen J.W. Direct effect of statins on homocysteine-induced endothelial adhesiveness: potential impact to human atherosclerosis. Eur. J. Clin. Invest. 2008, 38:106-116.
27. Liao J.K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am. J. Cardiol. 2005, 96:24F-33F.
28. Zhou Q., Liao J.K. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr. Pharm. Des. 2009, 15:467-478.
29. Di Napoli P., Taccardi A.A., Oliver M., De Caterina R. Statins and stroke: evidence for cholesterol-independent effects. Eur. Heart J. 2002, 23:1908-1921.
30. van Mil A.H., Westendorp R.G., Bollen E.L., Lagaay A.M., Blauw G.J. HMG-CoA reductase inhibitors in the prevention of stroke. Drugs 2000, 59:1-6.
31. Briaud I., Kelpe C.L., Johnson L.M., Tran P.O., Poitout V. Differential effects of hyperlipidemia on insulin secretion in islets of langerhans from hyperglycemic versus normoglycemic rats. Diabetes 2002, 51:662-668.
32. Goto Y., Suzuki K., Ono T., Sasaki M., Toyota T. Development of diabetes in the non-obese NIDDM rat. Adv. Exp. Med. Biol. 1988, 246:29-31.
33. Portha B., Serradas P., Bailbe D., Suzuki K., Goto Y., Giroix M.H. Beta-cell insensitivity to glucose in the GK rat, a spontaneous nonobese model for type II diabetes. Diabetes 1991, 40:486-491.
34. Sena C.M., Nunes E., Louro T., Proenca T., Fernandes R., Boarder M.R., Seica R.M. Effects of alpha-lipoic acid on endothelial function in aged diabetic and high-fat fed rats. Br. J. Pharmacol. 2008, 153:894-906.
35. van Leuven S.I., Kastelein J.J. Atorvastatin. Expert Opin. Pharmacother. 2005, 6:1191-1203.
36. Singh V., Deedwania P. Reducing morbidity and mortality in high risk patients with statins. Vasc. Health Risk Manag. 2009, 5:495-507.
37. Kumar A., Cannon C.P. Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention. J. Interv. Cardiol. 2007, 20:447-457.
38. Ji G., Zhao X., Leng L., Liu P., Jiang Z. Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats. Lipids Health Dis. 2011, 10:23.
39. Paraskevas K.I., Pantopoulou A., Vlachos I.S., Agrogiannis G., Iliopoulos D.G., Karatzas G., Tzivras D., Mikhailidis D.P., Perrea D.N. Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model. Angiology 2011, 62:144-154.
40. Shah D.I., Singh M. Effect of fasudil on macrovascular disorder-induced endothelial dysfunction. Can. J. Physiol. Pharmacol. 2006, 84:835-845.
41. Suzuki M., Kakuta H., Takahashi A., Shimano H., Tada-Iida K., Yokoo T., Kihara R., Yamada N. Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice. J. Atheroscler. Thromb. 2005, 12:77-84.
42. Hamed M.R., Hassanein N.M.A., Ali A.A., EL-Nahhas T.M.Y. An experimental study on the therapeutic efficacy of the combined administration of herbal medicines with atorvastatin against hyperlipidemia in rats. J. Appl. Sci. Res. 2010, 6:1730-1744.
43. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109:III39-43.
44. Ray K.K., Cannon C.P. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J. Am. Coll. Cardiol. 2005, 46:1425-1433.
45. Ray K.K., Cannon C.P., Ganz P. Beyond lipid lowering: what have we learned about the benefits of statins from the acute coronary syndromes trials?. Am. J. Cardiol. 2006, 98:18P-25P.
46. Yamagishi S., Matsui T., Nakamura K. Atorvastatin and diabetic vascular complications. Curr. Pharm. Des. 2006, 12:1549-1554.
47. Brumeanu T.D., Goldstein R., Casares S. Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors. Clin. Immunol. 2006, 119:1-12.
48. Li J., Schmidt A.M. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. 1997, 272:16498-16506.
49. Bierhaus A., Chevion S., Chevion M., Hofmann M., Quehenberger P., Illmer T., Luther T., Berentshtein E., Tritschler H., Muller M., Wahl P., Ziegler R., Nawroth P.P. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997, 46:1481-1490.
50. Mohamed A.K., Bierhaus A., Schiekofer S., Tritschler H., Ziegler R., Nawroth P.P. The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors 1999, 10:157-167.
51. Sharma I., Dhawan V., Mahajan N., Saha S.C., Dhaliwal L.K. In vitro effects of atorvastatin on lipopolysaccharide-induced gene expression in endometriotic stromal cells. Fertil. Steril. 2010, 94:1639-1646.
52. Rodriguez C., Alcudia J.F., Martinez-Gonzalez J., Guadall A., Raposo B., Sanchez-Gomez S., Badimon L. Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors. Cardiovasc. Res. 2009, 83:595-603.
53. Tanimoto A., Murata Y., Wang K.Y., Tsutsui M., Kohno K., Sasaguri Y. Monocyte chemoattractant protein-1 expression is enhanced by granulocyte-macrophage colony-stimulating factor via Jak2-Stat5 signaling and inhibited by atorvastatin in human monocytic U937 cells. J. Biol. Chem. 2008, 283:4643-4651.
54. Morikawa S., Takabe W., Mataki C., Kanke T., Itoh T., Wada Y., Izumi A., Saito Y., Hamakubo T., Kodama T. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J. Atheroscler. Thromb. 2002, 9:178-183.
55. Li J.Q., Zhao S.P., Li Q.Z., Cai Y.C., Wu L.R., Fang Y., Li P. Atorvastatin reduces plasminogen activator inhibitor-1 expression in adipose tissue of atherosclerotic rabbits. Clin. Chim. Acta 2006, 370:57-62.
56. Wagner A.H., Schwabe O., Hecker M. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br. J. Pharmacol. 2002, 136:143-149.
57. Zhao Y., Chan M.Y., Zhou S., Heng C.K. Effects of atherogenic diet and atorvastatin treatment on gene expression profiles in the C57BL/6J mouse liver. Gene Expr. 2008, 14:149-158.
58. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.J., Li H., Yasui K., Takeuchi M., Makita Z., Takasawa S., Okamoto H., Watanabe T., Yamamoto H. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 2003, 370:1097-1109.
59. Park I.H., Yeon S.I., Youn J.H., Choi J.E., Sasaki N., Choi I.H., Shin J.S. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol. Immunol. 2004, 40:1203-1211.
60. Hanford L.E., Enghild J.J., Valnickova Z., Petersen S.V., Schaefer L.M., Schaefer T.M., Reinhart T.A., Oury T.D. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J. Biol. Chem. 2004, 279:50019-50024.
61. Hudson B.I., Harja E., Moser B., Schmidt A.M. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein?. Arterioscler. Thromb. Vasc. Biol. 2005, 25:879-882.
62. Santilli F., Bucciarelli L., Noto D., Cefalu A.B., Davi V., Ferrante E., Pettinella C., Averna M.R., Ciabattoni G., Davi G. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic. Biol. Med. 2007, 43:1255-1262.
63. Tam H.L., Shiu S.W., Wong Y., Chow W.S., Betteridge D.J., Tan K.C. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2009, 209:173-177.
64. Cipollone F., Fazia M., Iezzi A., Zucchelli M., Pini B., De Cesare D., Ucchino S., Spigonardo F., Bajocchi G., Bei R., Muraro R., Artese L., Piattelli A., Chiarelli F., Cuccurullo F., Mezzetti A. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 2003, 107:1479-1485.
65. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103:926-933.
66. Rahbar S., Figarola J.L. Novel inhibitors of advanced glycation endproducts. Arch. Biochem. Biophys. 2003, 419:63-79.
67. Bierhaus A., Hofmann M.A., Ziegler R., Nawroth P.P. AGE and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc. Res. 1998, 37:586-600.
68. Okamoto T., Yamagishi S., Inagaki Y., Amano S., Koga K., Abe R., Takeuchi M., Ohno S., Yoshimura A., Makita Z. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J. 2002, 16:1928-1930.
69. Jinnouchi Y., Yamagishi S., Takeuchi M., Ishida S., Jinnouchi Y., Jinnouchi J., Imaizumi T. Atorvastatin decreases serum levels of advanced glycation end products (AGE) in patients with type 2 diabetes. Clin. Exp. Med. 2006, 6:191-193.